World Journal of Hepatology · 2020 · 42 citations · 16 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyHepatic PharmacotherapyHepatologyBiomarkers Of Liver InjuryCirrhosisHepatic ImpairmentLiver DiseaseAspartate Aminotransferase ElevationFatty InfiltrationHepatic Steatosis AssessmentPcsk9 Inhibitor TherapyPcsk9 InhibitorsProprotein Convertase Subtilisin/kexin Type 9 InhibitionProprotein ConvertasesSerum Aspartate Aminotransferase
BACKGROUND: Many studies have investigated the progression of nonalcoholic fatty liver disease (NAFLD) and its predisposing risk factors, but the conclusions from these studies have been conflicting. More challenging is the fact that no effective treatment is currently available for NAFLD. AIM: To determine the effects of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors on fatty infiltration of the liver. METHODS: -test (alpha criterion: 0.05). RESULTS: = 0.201). CONCLUSION: PCSK9 inhibitors can slow down or even completely resolve NAFLD.
16
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.3K citations · Full text
Stuart McPherson, Timothy Hardy, Elsbeth Henderson et al. · Journal of Hepatology · 2014 · 1K citations · Full text